Dizal (Jiangsu) Pharmaceutical Co. Ltd. A
Dizal (Jiangsu) Pharmaceutical Co., Ltd., a biopharmaceutical company, discovers, develops, and commercializes therapeutics for the treatment of cancer and immunological diseases. Its assets include the ZEGFROVY, for the treatment of solid tumors; Golidocitinib to treat hematological malignancy, solid tumors, and immunological diseases; Birelentinib indicated for hematological malignancy; DZD2269… Read more
Dizal (Jiangsu) Pharmaceutical Co. Ltd. A - Asset Resilience Ratio
Dizal (Jiangsu) Pharmaceutical Co. Ltd. A (688192) has an Asset Resilience Ratio of 31.26% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2024)
This chart shows how Dizal (Jiangsu) Pharmaceutical Co. Ltd. A's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Dizal (Jiangsu) Pharmaceutical Co. Ltd. A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥1.01 Billion | 31.26% |
| Total Liquid Assets | CN¥1.01 Billion | 31.26% |
Asset Resilience Insights
- Very High Liquidity: Dizal (Jiangsu) Pharmaceutical Co. Ltd. A maintains exceptional liquid asset reserves at 31.26% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Dizal (Jiangsu) Pharmaceutical Co. Ltd. A Industry Peers by Asset Resilience Ratio
Compare Dizal (Jiangsu) Pharmaceutical Co. Ltd. A's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF |
Drug Manufacturers - Specialty & Generic | -0.02% |
|
Kamada
NASDAQ:KMDA |
Drug Manufacturers - Specialty & Generic | 21.63% |
|
Dongwha Pharm.Co.Ltd
KO:000020 |
Drug Manufacturers - Specialty & Generic | 1.92% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.46% |
|
Yuhan Corp.
KO:000100 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
|
Kotra Industries Bhd
KLSE:0002 |
Drug Manufacturers - Specialty & Generic | 9.82% |
|
Yuyu Pharma Inc
KO:000227 |
Drug Manufacturers - Specialty & Generic | 1.74% |
Annual Asset Resilience Ratio for Dizal (Jiangsu) Pharmaceutical Co. Ltd. A (2019–2024)
The table below shows the annual Asset Resilience Ratio data for Dizal (Jiangsu) Pharmaceutical Co. Ltd. A.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 34.32% | CN¥589.83 Million | CN¥1.72 Billion | -10.72pp |
| 2023-12-31 | 45.04% | CN¥674.00 Million | CN¥1.50 Billion | -17.15pp |
| 2022-12-31 | 62.19% | CN¥1.29 Billion | CN¥2.08 Billion | -0.12pp |
| 2021-12-31 | 62.31% | CN¥1.71 Billion | CN¥2.75 Billion | +54.88pp |
| 2020-12-31 | 7.43% | CN¥90.29 Million | CN¥1.22 Billion | +5.45pp |
| 2019-12-31 | 1.98% | CN¥12.45 Million | CN¥627.36 Million | -- |